Relugolix Combination Tablet
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids
Conditions
Uterine Fibroids, Endometriosis
Trial Timeline
Aug 14, 2023 → Sep 1, 2030
NCT ID
NCT05862272About Relugolix Combination Tablet
Relugolix Combination Tablet is a phase 3 stage product being developed by Sumitomo Pharma for Uterine Fibroids. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05862272. Target conditions include Uterine Fibroids, Endometriosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05862272 | Phase 3 | Recruiting |
Competing Products
20 competing products in Uterine Fibroids